“Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary Analysis.”, JAMA Netw Open, vol. 2, no. 9, p. e1910769, 2019.
, “Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial.”, JAMA Neurol, vol. 76, no. 7, pp. 774-782, 2019.
, “Screen failure data in clinical trials: Are screening logs worth it?”, Clin Trials, vol. 11, no. 4, pp. 467-472, 2014.
, “Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient Ischemic Attack and Minor Ischemic Stroke.”, Circulation, vol. 140, no. 8, pp. 658-664, 2019.
,